Connect Biopharma Holdings Limited

NASDAQ:CNTB

Biotechnology

Healthcare
$0.80 -4.09%

-$0.09 today

Market cap
$50.52M
Beta
-0.21
P/E (TTM)
-4.0
EPS (TTM)
-$0.50
52W Low $0.91High $3.82

Volume 2.50M

Average 0.30M

CNTB Operating Cash Flow

Cash generated by the company's core business operations during the period.

Connect Biopharma Holdings LimitedNASDAQ: CNTB

Operating Cash Flow · Q4 FY2025 · quarter ended Dec 2025

Operating cash flow declines year over year

Q4 FY2025 operating cash flow of $11.25M (cash outflow) fell 27.8% year over year. Over 3 fiscal years it compounded at -19.8% a year.

Context

  • Operating cash flow amounted to 80009.4% of revenue in FY2025, up 79918.7 pp from a year earlier.
  • Operating cash flow grew in size in 1 of the last 3 fiscal years.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-$11.25M— QoQ
Last fiscal yearDec 2025
-$51.21M+116.9% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-27.8%——
1 year+116.9%——
3-year CAGR-19.8%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(51.21M) USD
Year-over-year change
-116.9%

Operating Cash Flow vs competitors

How CNTB compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +116.9% is the highest of 8, against a peer median of -15.3%.
  • Operating cash flow amounts to 80009.4% of revenue for CNTB, versus a peer median of 2358.2%.
CNTB Competitors
Operating Cash Flow for CNTB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$151.61M USD-22.1%—152.2%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$77.86M USD+30.2%+14.7%—
IMAImageneBio IncLTM Mar 2026$52.08M USD+36.1%-13.6%—
CNTBConnect Biopharma Holdings LimitedFY2025$51.21M USD+116.9%-19.8%80009.4%
KLRSKalaris Therapeutics IncLTM Mar 2026$48.89M USD—+63.8%—
OVIDOvid Therapeutics Inc.LTM Mar 2026$41.95M USD-15.3%-11.5%589.1%
STTKShattuck Labs, Inc.LTM Mar 2026$41.27M USD-26.8%-25.0%4127.4%
CNTXContext Therapeutics Inc.LTM Mar 2026$32.79M USD+115.4%+24.9%—
IFRXInflaRx N.V.LTM Mar 2026€28.81M EUR-39.6%+0.2%98232.5%
Peer median (excluding CNTB) —-15.3%+0.2%2358.2%

Competitors are the stored peer set for CNTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(204.94M)(116.12M)(59.38M)(15.63M)(55.48M)
Depreciation & Amortization640.98K1.01M988K660K704K
Deferred Income Tax106.37M3.37M000
Stock-Based Compensation1.41M1.01M3.26M6.73M3.73M
Change in Working Capital3.27M7.16M9.49M(15.49M)580K
Accounts Receivables(2.53K)3.37K1.04M(789K)776K
Inventory2.53K(3.37K)000
Accounts Payables8.89M375.66K(4.28M)(1.87M)1.62M
Other Working Capital(5.62M)6.78M12.72M(12.83M)(1.82M)
Other Non-Cash Items6.91K(1.35M)(2.28M)118K(736K)
Operating Cash Flow(85.57M)(99.27M)(47.93M)(23.61M)(51.21M)
Capital Expenditures(7.46M)(4.28M)(294K)(750K)(434K)
Acquisitions (Net)47.74K79.16K2.94M00
Purchases of Investments(17.98M)(113.7M)(32.6M)(15.45M)(30.47M)
Sales of Investments20.1M34.54M105.19M12.63M39.95M
Other Investing Activities(47.74K)(79.16K)(84K)123K775K
Investing Cash Flow(5.34M)(83.44M)75.16M(3.45M)9.82M
Debt Repayment(126K)(222K)(290K)00
Common Stock Issued219.99M18K44K227K1.09M
Common Stock Repurchased(566K)0000
Dividends Paid00000
Other Financing Activities(19.12M)119K000
Financing Cash Flow206.66M(91.29K)(246K)227K1.09M
Effect of Forex Changes(6.34M)13.87M18K(595K)408K
Net Change in Cash109.42M(168.93M)27M(27.43M)(39.89M)
Free Cash Flow(93.03M)(103.55M)(48.22M)(24.36M)(51.64M)

Connect Biopharma Holdings Limited

NASDAQ:CNTB

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.